Study shows long-term benefit with ReNeuron’s stroke therapy
ReNeuron’s CTX cell therapy candidate has been shown to improve neurological function in patients with stable motor disability following a stroke for at least 24 months, according to long-term data from a Phase I trial published by The Lancet.
Read More
